

# Jessica Cusato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8127917/publications.pdf>

Version: 2024-02-01

136  
papers

2,498  
citations

201658

27  
h-index

265191

42  
g-index

137  
all docs

137  
docs citations

137  
times ranked

3773  
citing authors

#	ARTICLE	IF	CITATIONS
1	25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. <i>Nutrients</i> , 2020, 12, 1359.	4.1	337
2	Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 391.e1-391.e7.	1.3	94
3	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1772-1777.	3.0	69
4	LC-MS application for therapeutic drug monitoring in alternative matrices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 40-51.	2.8	67
5	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 59, 109-116.	2.8	66
6	Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2976-2978.	3.2	64
7	Cannabinoids concentration variability in cannabis olive oil galenic preparations. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 70, 143-149.	2.4	59
8	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 54, 779-788.	2.8	58
9	The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy. <i>Journal of Medical Virology</i> , 2021, 93, 537-540.	5.0	50
10	Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B eAg negative and genotype D. <i>Liver International</i> , 2013, 33, 580-585.	3.9	40
11	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 197-203.	2.4	40
12	Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2645-2649.	3.0	39
13	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 535-541.	2.8	39
14	Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 165-170.	2.0	37
15	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 293-300.	1.5	37
16	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3061-3066.	3.0	36
17	Determinants of darunavir cerebrospinal fluid concentrations. <i>Aids</i> , 2012, 26, 1529-1533.	2.2	34
18	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. <i>Antiviral Research</i> , 2014, 102, 35-43.	4.1	34

#	ARTICLE	IF	CITATIONS
19	Therapeutic drug monitoringâ€“guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2535-2543.	2.4	34
20	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 936, 42-47.	2.3	33
21	UHPLCâ€“MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 279-285.	2.8	33
22	Role of <sc>CYP</sc>27<sc>B</sc>1+2838 promoter polymorphism in the treatment of chronic hepatitis <sc>B HB</sc>e<sc>A</sc>g negative with <sc>PEG</sc>â€“interferon. <i>Journal of Viral Hepatitis</i> , 2015, 22, 318-327.	2.0	32
23	Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 722-728.	2.0	31
24	Treatment with directâ€“acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 850-857.	2.0	31
25	Influence of <i>CYP2B6</i> and <i>ABCB1</i> SNPs on nevirapine plasma concentrations in Burundese HIVâ€“positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 134-140.	2.4	30
26	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. <i>Antiviral Research</i> , 2013, 100, 114-119.	4.1	27
27	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 241-245.	3.0	27
28	Development and validation of a useful HPLCâ€“UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 66, 376-380.	2.8	26
29	Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2017, 56, 355-369.	3.5	26
30	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011, 54, 2279-2279.	7.3	25
31	Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. <i>Journal of Viral Hepatitis</i> , 2014, 21, 260-263.	2.0	24
32	Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , 2016, 16, 514-518.	2.0	24
33	<i>SLC22A2</i> variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1035-1043.	3.0	24
34	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018, 19, 913-925.	1.3	23
35	The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon. <i>Journal of Infection</i> , 2014, 69, 81-87.	3.3	22
36	Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness. <i>Pharmacogenomics Journal</i> , 2015, 15, 263-271.	2.0	22

#	ARTICLE	IF	CITATIONS
37	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 117-123.	2.5	22
38	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 907-910.	3.0	21
39	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. <i>Antiviral Therapy</i> , 2014, 20, 335-341.	1.0	21
40	Pharmacogenetics of ribavirin-induced anemia in HCV patients. <i>Pharmacogenomics</i> , 2016, 17, 925-941.	1.3	21
41	A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 145, 718-724.	2.8	20
42	Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery. <i>Journal of Reproductive Immunology</i> , 2021, 144, 103285.	1.9	18
43	Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. <i>Pharmacogenomics</i> , 2017, 18, 651-661.	1.3	17
44	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 1083-1088.	1.9	17
45	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017, 5, 66.	3.2	17
46	Obstetric and neonatal outcomes after SARS-CoV-2 infection in the first trimester of pregnancy: A prospective comparative study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 393-401.	1.3	17
47	Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 853-858.	2.0	16
48	UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 64-69.	2.8	16
49	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018, 19, 145-165.	1.3	16
50	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016, 17, 571-582.	1.3	15
51	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3096-3099.	3.0	14
52	Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 47-55.	5.6	14
53	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017, 18, 539-554.	1.3	14
54	A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 602-609.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Wastewater-based SARS-CoV-2 environmental monitoring for Piedmont, Italy. <i>Environmental Research</i> , 2022, 203, 111901.	7.5	14
56	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 63-69.	5.6	13
57	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017, 18, 865-880.	1.3	13
58	The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 450-457.	4.7	13
59	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , 2014, 109, 7-14.	4.1	12
60	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016, 30, 915-920.	2.2	12
61	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 164-172.	1.5	11
62	Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. <i>Antiviral Research</i> , 2016, 136, 32-36.	4.1	11
63	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017, 45, 103-106.	4.7	11
64	Effect of <i>ABCC2</i> and <i>ABCG2</i> Gene Polymorphisms and CSF to Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1550-1556.	2.0	11
65	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 125.	3.7	11
66	Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. <i>Diagnostics</i> , 2021, 11, 867.	2.6	11
67	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 307-308.	3.0	10
68	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 657-661.	2.5	10
69	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 307-310.	1.5	10
70	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016, 497, 287-292.	5.2	10
71	Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1659-1664.	3.0	10
72	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 615-620.	2.3	10

#	ARTICLE	IF	CITATIONS
73	Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. <i>Pharmacogenomics Journal</i> , 2018, 18, 506-515.	2.0	10
74	Cerebral white matter Hyperintensities in HIV“positive patients. <i>Brain Imaging and Behavior</i> , 2020, 14, 10-18.	2.1	10
75	Identification of na“ve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , 2014, 106, 105-110.	4.1	9
76	Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 171.	2.1	9
77	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. <i>Archives of Virology</i> , 2015, 160, 2009-2017.	2.1	9
78	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1155-1157.	1.9	9
79	Deferasirox pharmacokinetic and toxicity correlation in $\beta^2$ -thalassaemia major treatment“. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 1417-1421.	2.4	9
80	Estimating ribavirin plasma exposure: Genetics or therapeutic drug monitoring?. <i>Journal of Hepatology</i> , 2013, 59, 633-634.	3.7	8
81	Influence of ABCB11 and HNF4“ genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2846-2849.	3.0	8
82	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma“. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1524-1530.	2.4	8
83	Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-na“ve patients with chronic hepatitis B. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 324-327.	2.5	7
84	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 135-138.	3.0	7
85	Prenatal Biochemical and Ultrasound Markers in COVID-19 Pregnant Patients: A Prospective Case-Control Study. <i>Diagnostics</i> , 2021, 11, 398.	2.6	7
86	Real“life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID“19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4861-4867.	2.4	7
87	Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 210, 105854.	2.5	7
88	Preterm birth is not associated with asymptomatic/mild SARS-CoV-2 infection per se: Pre-pregnancy state is what matters. <i>PLoS ONE</i> , 2021, 16, e0254875.	2.5	7
89	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2021, 14, 12.	3.8	7
90	Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 604-606.	2.0	6

#	ARTICLE	IF	CITATIONS
91	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 17-22.	1.5	6
92	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018, 94, 29-35.	0.7	6
93	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 417-427.	2.0	6
94	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021, 60, 89-102.	3.5	6
95	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. <i>Biomedicines</i> , 2021, 9, 1288.	3.2	6
96	Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. <i>Infection, Genetics and Evolution</i> , 2017, 53, 195-198.	2.3	6
97	Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage. <i>Antiviral Research</i> , 2015, 116, 45-47.	4.1	5
98	Deferasirox pharmacokinetic evaluation in $\beta$ -thalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 525-528.	2.4	5
99	Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. <i>Journal of NeuroVirology</i> , 2018, 24, 132-136.	2.1	5
100	Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. <i>Archives of Virology</i> , 2018, 163, 961-967.	2.1	5
101	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 405-412.	1.6	5
102	Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma. <i>Separations</i> , 2021, 8, 189.	2.4	5
103	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. <i>Frontiers in Pharmacology</i> , 2021, 12, 755184.	3.5	5
104	A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients. <i>Irish Journal of Medical Science</i> , 2023, 192, 423-430.	1.5	5
105	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. <i>Pharmacogenomics</i> , 2017, 18, 607-611.	1.3	4
106	The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 965-968.	1.9	4
107	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. <i>Infection, Genetics and Evolution</i> , 2018, 60, 42-47.	2.3	4
108	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 202-212.	2.0	4

#	ARTICLE	IF	CITATIONS
109	COVID-19: unanswered questions and work for a better knowledge. <i>Minerva Medica</i> , 2021, 112, 111-113.	0.9	4
110	Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. <i>Pharmaceuticals</i> , 2021, 14, 462.	3.8	4
111	Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. <i>Pharmaceuticals</i> , 2021, 14, 1230.	3.8	4
112	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous $\beta$ -thalassaemia. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1510-1512.	5.6	3
113	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. <i>Infection, Genetics and Evolution</i> , 2017, 51, 167-172.	2.3	3
114	Correlation between Entecavir Penetration in Peripheral Blood Mononuclear Cells and HBV DNA Decay during Treatment of HBeAg-Negative Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2018, 23, 373-377.	1.0	3
115	Clinical relevance of deferasirox trough levels in $\beta$ -thalassaemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 213-216.	1.9	3
116	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	3
117	Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 263-272.	4.0	3
118	Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. <i>Biomedicines</i> , 2021, 9, 1202.	3.2	3
119	Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. <i>Digestive and Liver Disease</i> , 2017, 49, 705-708.	0.9	2
120	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 199-206.	1.5	2
121	Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis. <i>European Addiction Research</i> , 2018, 24, 184-188.	2.4	2
122	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 202-204.	1.8	2
123	Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. <i>Pharmaceuticals</i> , 2021, 14, 460.	3.8	2
124	Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. <i>Nutrients</i> , 2021, 13, 3571.	4.1	2
125	Monthly Increase in Vitamin D Levels upon Supplementation with 2000 IU/Day in Healthy Volunteers: Result from "Integriamoci", a Pilot Pharmacokinetic Study. <i>Molecules</i> , 2022, 27, 1042.	3.8	2
126	The Role of IL28B Genotype in HCV-RNA Baseline Levels. <i>Intervirology</i> , 2016, 59, 67-68.	2.8	1



#	ARTICLE	IF	CITATIONS
127	Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. <i>European Journal of Public Health</i> , 2017, 27, 938-941.	0.3	1
128	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. <i>Pharmacogenomics</i> , 2018, 19, 701-707.	1.3	1
129	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentrationâ€”Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 254-255.	2.0	1
130	Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study. <i>Archives of Virology</i> , 2021, 166, 1125-1131.	2.1	1
131	Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. <i>Diagnostics</i> , 2021, 11, 869.	2.6	1
132	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. <i>Blood</i> , 2012, 120, 4903-4903.	1.4	1
133	A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy. <i>Phytomedicine</i> , 2022, 102, 154218.	5.3	1
134	A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis. <i>Minerva Biotechnology and Biomolecular Research</i> , 2022, 33, .	0.5	0
135	Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in) Tj ETQq1 1 0.784314 rgBT /Overlock	3.8	0
136	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. <i>Pharmaceuticals</i> , 2022, 15, 630.	3.8	0